Danaher
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after CEO sees faster gr...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commer...
Latest News
7 days ago · marketbeat.com
Danaher CEO Sees Faster Growth Ahead, With AI and Acquisitions in FocusDanaher NYSE: DHR President and CEO Julie Sawyer Montgomery said the company is aiming for faster core growth and market share gains through stronger commercial execution, innovation and acquisitions, as it pursues a leadership position in life sciences and diagnostics.
8 days ago · seekingalpha.com
Danaher Corporation (DHR) Presents at 2026 UBS Global Healthcare Conference TranscriptDanaher Corporation (DHR) Presents at 2026 UBS Global Healthcare Conference Transcript
14 days ago · prnewswire.com
Danaher to Present at UBS Global and Jefferies Global Healthcare ConferencesWASHINGTON, Nov. 2, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Julie Sawyer Montgomery, will be presenting at the UBS Global Healthcare Conference in Palm Beach, Florida on Monday, November 9, 2026 at 11:45 a.m. ET and Jefferies Global Healthcare Conference in London, UK on November 17, 2026 at 10:00 a.m.
21 days ago · zacks.com
Danaher (DHR) Upgraded to Buy: Here's WhyDanaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
26 days ago · zacks.com
LH vs. DHR: Which Stock Is the Better Value Option?Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
26 days ago · seekingalpha.com
Danaher Q3 Recap: Decent Results, Still A HoldDanaher Corporation is rated hold, as the stock trades at a small premium and offers an 8.85% expected return, below my threshold. Q3 earnings showed solid performance: revenue up 8.3% YoY to $6.55B, adjusted EPS of $2.11, and strong segment growth, especially in Diagnostics. Key headwinds include respiratory revenue volatility and pricing pressure from China's volume-based procurement, despite some recent positive trends.
26 days ago · fool.com
Why Danaher Stock Bounced Higher TodayIt beat analyst estimates for both revenue and profitability. Its full-year earnings guidance also topped the pundit consensus.
26 days ago · seekingalpha.com
Danaher Corporation (DHR) Q3 2026 Earnings Call TranscriptDanaher Corporation ( DHR ) Q3 2026 Earnings Call October 21, 2026 8:00 AM EDT Company Participants Rachel Vatnsdal Olson - Vice President of Investor Relations Julie Montgomery - President, CEO & Director Matthew Gugino - Executive VP & CFO Conference Call Participants Doug Schenkel Vijay Kumar - Evercore ISI Institutional Equities, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Operon Research, LLC Scott Davis - Melius Research LLC Casey Woodring - JPMorgan Chase & Co, Research Division Elizabeth Koslosky - Goldman Sachs Group, Inc., Research Division Presentation Operator My name is Chelsea, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Third Quarter 2026 Earnings Results Conference Call.
26 days ago · fool.com
Danaher: 3 Key Takeaways for Long-Term InvestorsDanaher raised full-year earnings per share guidance to $8.57 to $8.62. Biotechnology orders grew mid-teens during the third quarter.
27 days ago · seekingalpha.com
Danaher Q3 Review: Interested To See What The New Management Will BringDanaher Corporation delivered mixed Q3 results, with revenue up 8.3% y/y but growth driven mainly by acquisitions and tariff refunds. Adjusted operating margin reached 29%, exceeding guidance, yet organic growth and profitability improvements remain modest and partly non-recurring. Management's Q4 guidance implies lower-than-expected EPS, and the new CEO signals a need for stronger growth and operational execution.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove DHR